Key Highlights

  • ALT reported a second-quarter 2026 net loss of $22.8 million, or $0.12 per share, with adjusted EPS beating the negative $0.15 estimate by 20 percent.
  • The company initiated its global Phase 3 PERFORMA trial evaluating pemvidutide in MASH, with a 52-week data readout expected in 2029.
  • Pemvidutide met its primary endpoint in the Phase 2 RECLAIM trial for alcohol use disorder, showing a statistically significant 1.45 heavy-drinking-days-per-week reduction versus placebo.
  • The company held total cash of $519 million as of June 30, providing runway through the MASH Phase 3 52-week readout, following approximately $310 million raised year to date.

PERFORMA Trial Launch Marks Transition to Late-Stage Company

Altimmune, Inc. (NASDAQ:ALT), a Gaithersburg, Maryland-based clinical-stage biopharmaceutical company focused on serious liver diseases, began enrolling patients in its global Phase 3 PERFORMA trial for pemvidutide in MASH just three months after securing the financial resources needed to fund the study through its 52-week readout. The trial will span approximately 300 sites, with one-third in the United States and two-thirds outside the country, and management said enrollment is being targeted toward the faster end of the typical 18-to-24-month range for trials of this type.

Because MASH Drug Development remains a competitive space with multiple other Phase 3 programs enrolling concurrently, the company's ability to hit its targeted enrollment pace will depend on continued site engagement and favorable trial design features such as AI-assisted pathology reading, which management said has reduced screen failure rates relative to earlier trials.

Alcohol Use Disorder Data Opens a Second Liver Franchise Opportunity

The Phase 2 RECLAIM trial met its primary endpoint with a statistically significant reduction in heavy drinking days, alongside two additional endpoints recognized by the FDA as potentially registrational: a two-level reduction in World Health Organization risk drinking levels and an increase in the percentage of patients achieving zero heavy drinking days. Pemvidutide also produced a 9.1 percent reduction in body weight versus placebo and showed exploratory improvement in a liver fibrosis risk biomarker among patients with elevated baseline levels.

Management plans to request an end-of-Phase 2 meeting with the FDA to discuss a Phase 3 program that would broaden eligibility to include patients with lower body mass index and potentially explore a lower dosing option, though the ultimate trial design remains subject to regulatory feedback that has not yet occurred.

Financing Strategy Prioritizes Non-Dilutive Options for AUD Program

The company's $519 million cash balance, following approximately $310 million raised so far in 2026, fully funds its confirmed obligations through the MASH Phase 3 52-week data readout but does not include funding for a potential Phase 3 trial in alcohol use disorder. Management said its preference is to fund that program through non-dilutive means such as Royalty arrangements, debt, or strategic partnerships once the scope of the required study becomes clearer following regulatory discussions, though it noted the AUD Phase 3 is expected to be considerably less costly than the ongoing MASH program.

Conclusion

Altimmune's positive AUD data alongside the initiation of its pivotal MASH trial gives the company two potential paths toward building what it describes as a broader liver disease franchise around pemvidutide. The company's ability to secure non-dilutive financing for a Phase 3 AUD program, together with continued execution on PERFORMA enrollment, will likely determine the pace at which this dual-indication strategy advances over the coming years.